Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.
Published version of a preprint
The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Abstract
Alterations in EGFR, KRAS, and ALK are oncogenic drivers in lung cancer, but how oncogenic signaling influences immunity in the tumor microenvironment is just beginning to be understood. Immunosuppression likely contributes to lung cancer, because drugs that inhibit immune checkpoints like PD-1 and PD-L1 have clinical benefit. Here, we show that activation of the AKT–mTOR pathway tightly regulates PD-L1 expression in vitro and in vivo. Both oncogenic and IFNγ-mediated induction of PD-L1 was dependent on mTOR. In human lung adenocarcinomas and squamous cell carcinomas, membranous expression of PD-L1 was significantly associated with mTOR activation. These data suggest that oncogenic activation of the AKT–mTOR pathway promotes immune escape by driving expression of PD-L1, which was confirmed in syngeneic and genetically engineered mouse models of lung cancer where an mTOR inhibitor combined with a PD-1 antibody decreased tumor growth, increased tumor-infiltrating T cells, and decreased regulatory T cells. Cancer Res; 76(2); 227–38. ©2015 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A series of preclinical studies has shown that PI3K/AKT induces high expression of PD-L1 in colon cancer stem cells and mediates immune escape [226,227].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [226]
In the citing paper
“Inhibition of the PI3K/AKT/mTOR pathway improves the efficacy of anti-PD-1 and anti-CTLA-4 antibodies in mouse models [226,230,231].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [226]
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationSiegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 2×
“The combination of rapamycin and a PD-1 blocking antibody decreases lung tumor growth Monoclonal antibodies that block PD-L1 or PD-1 have shown clinical benefit in NSCLC (9, 10).”
BackgroundMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 4×
“AKT/mTOR activation was detected in adenocarcinoma and squamous cell carcinoma cell lines with mutations in NRAS (H1299), KRAS (H157/A549), EGFR (H1975/H1650), BRAF (H2087), PIK3CA (H1650), EML4-ALK (H3122), RET (H1563), autocrine productionof FGF2 (H226), or FGFR1 amplification (H520; Fig.”
BackgroundInfluentialPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 1×
“In addition to PD-L1 expression, it is possible that response to PD-1 or PD-L1 blockade depends on a critical threshold of TILs at the start of therapy (50).”
BackgroundTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496 · cited 1×
“Although multiple mechanisms can contribute to immune suppression in the tumormicroenvironment, programmed death ligand 1 (PD-L1 and B7-H1), an inhibitory member of the B7 family, plays a central role in many cancer types (6).”
BackgroundTaube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Self-citation
Cited by
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
“…mechanisms that have been described as leading to constitutive PD-L1 expression by cancer cells include PTEN deletions or PI3K and/or AKT mutations (Lastwika et al., 2016; Parsa et al., 2007), EGFR mutations (Akbay et al., 2013), MYC overexpression (Casey et al., 2016), CDK5 disruption (Dorand et…”
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
“PI3K/mTOR pathway activation in lung cancer models was associated with increased expression of the PD-1 ligand PD-L1, and combination therapy with rapamycin plus anti-PD1 antibody significantly reduced tumor burden in a KRAS -driven mouse NSCLC model (Lastwika et al., 2016).”
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Targeting PI3K/Akt signal transduction for cancer therapy
He, Y., Sun, M. M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 1,892
“In mouse lung cancer models and human lung cancer cell lines, the Akt signaling pathway regulates the expression of PD-L1 at the protein translation level.(146) In conclusion, the PI3K/Akt signaling pathway is obviously related to immune resistance, which provides a basis for combined therapeutic strategies including…”
BackgroundPI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
“In syngeneic and genet-ically-engineered mouse models of lung cancer, inhibition of mTOR bolsters the effects of PD-1 blockade [422].”
Background
Metadata
- Authors
- Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., Liu, L. N., Gills, J. J., & Dennis, P. A.
- Affiliations
- Johns Hopkins University (US)
- National Institutes of Health (US)
- Amplimmune (United States) (US)
- ORCID
- Venue
- Cancer Research
- Published
- 2016-01-14
- Volume
- 76
- Issue
- 2
- Pages
- 227-238
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2196159484
- Cited by
- 785
- References
- 52
- Citations by year
- 2026: 32 · 2025: 73 · 2024: 69 · 2023: 80 · 2022: 89 · 2021: 98 · 2020: 102 · 2019: 75 · 2018: 74 · 2017: 61 · 2016: 31
- FWCI
- 24.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- PD-L1 expression, Akt/mTOR signaling, non-small cell lung cancer, tumor immune microenvironment, immune evasion, mTOR inhibition, anti-PD-1, interferon-gamma, lung adenocarcinoma, lung squamous cell carcinoma, regulatory T cells, tumor-infiltrating T cells, oncogenic signaling
- MeSH terms
- Animals, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Transfection, Oncogene Protein v-akt, Mice, TOR Serine-Threonine Kinases, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-14-3362
- The paper
- Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., Liu, L. N., Gills, J. J., & Dennis, P. A. (2016). Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-14-3362
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.